Clinical trials: Upper Tract Urothelial Cancer
Upper Urinary Tract Urothelial Carcinoma
HERO-UTUC: Intravesical RC48 After RNU for HER2+ UTUC
This is a prospective, single-center, single-arm phase II study evaluating whether a single postoperative intravesical instillation of disitamab vedotin (RC48) can reduce bladder recurrence after radical nephroureterectomy (RNU)…
- Trial name
- HERO-UTUC (NCT07591805)
- Testing
- Drug: Disitamab Vedotin
- Where
- China
- Volunteers
- 49 people
- Sponsor
- RenJi Hospital
Upper Tract Urothelial Carcinoma
Biomarker-Enriched Kidney-Preserving Strategy With Disitamab Vedotin Plus Tislelizumab in HER2-Positive High-Risk Upper Tract Urothelial Carcinoma
This is a prospective, multicentre, single-arm phase II study evaluating a response-adapted kidney-preserving strategy in patients with HER2-positive high-risk upper tract urothelial carcinoma (UTUC).
- Trial name
- NCT07584733
- Testing
- RC48 Combined With Tislelizumab
- Where
- China
- Volunteers
- 50 people
- Sponsor
- RenJi Hospital
Urinary Bladder Cancer, Upper Tract Urothelial Cancer
SeqUential GeMcitabine and MITomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma
This Phase II clinical trial, titled "A Phase II Trial of Sequential Gemcitabine and Mitomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma (SUMMIT)," aims to evaluate the safety and effectiveness of…
- Conditions
- Urinary Bladder Cancer, Upper Tract Urothelial Cancer, Urothelial Cancer
- Trial name
- NCT06822010
- Testing
- Sequential Gemcitabine and Jelmyto Treatment (Gem/Jel)
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Rutgers, The State University of New Jersey
Upper Tract Urothelial Carcinoma Receiving Kidney-sparing Therapy, Upper Tract Urothelial Carcinoma
Multimodal Kidney-Sparing Strategy for High-Risk Upper Tract Urothelial Carcinoma
UTUC is a cancer that develops in the lining of the kidney or ureter. The standard treatment is radical nephroureterectomy, which removes the kidney and ureter.
- Trial name
- NCT07504939
- Testing
- SBRT
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Peking University First Hospital
Neoadjuvant Therapy, Urothelial Carcinoma Ureter
Neoadjuvant Chemotherapy Before Surgery vs Surgery Alone for UTUC: A Randomized Trial
This clinical trial aims to compare the effectiveness and safety of two treatment options for patients with high-risk upper tract urothelial carcinoma (UTUC).
- Conditions
- Neoadjuvant Therapy, Urothelial Carcinoma Ureter, Upper Urinary Tract Urothelial Carcinoma
- Trial name
- NCT07492225
- Testing
- Neoadjuvant Gemcitabine + Cisplatin Chemotherapy
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Changhai Hospital
Bladder Cancer, Urothelial Carcinoma
Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma
This hypothetical first-in-human study is designed to evaluate the safety, feasibility, and preliminary anti-tumor activity of an allogeneic dual-target Nectin-4/HER2 CAR-NK cell product in adults with relapsed/refractory locally…
- Conditions
- Bladder Cancer, Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
- Trial name
- DUET-UC-NK (NCT07492628)
- Testing
- EB-DT-NK-UC101, Cyclophosphamide, Fludarabine
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Beijing Biotech
Upper Tract Urothelial Carcinoma
NECTAR Study: Neoadjuvant Toripalimab + 9MW2821 for Local UTUC
The NECTAR study is a multicenter, open-label, randomized phase II clinical trial designed to evaluate a neoadjuvant treatment strategy in patients with localized upper tract urothelial carcinoma (UTUC).
- Trial name
- NECTAR (NCT07412171)
- Testing
- Toripalimab, 9MW2821, Radical Nephroureterectomy with or without Lymph Node Dissection
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking University Third Hospital
Upper Urinary Tract Urothelial Carcinoma
The Danish Bladder Cancer Group 23 Study - A European Study on Cancer in the Upper Urinary Tract
This is a study looking at how patients with a rare type of cancer in the pelvis and ureter of the kidney - called upper urinary tract urothelial carcinoma (UTUC) - is currently treated.
- Trial name
- EuroCUT (NCT07077447)
- Testing
- Kidney sparing surgery for high-risk upper urinary tract urothelial carcinoma
- Where
- 5 sites in Denmark, Norway
- Volunteers
- 2,500 people
- Sponsor
- Zealand University Hospital
Upper Urinary Tract Urothelial Carcinoma
A Clinical Study of the Efficacy and Safety of Disitamab Vedotin in Combination With Radiotherapy for the Adjuvant Treatment of HER2 Overexpressing UTUC Patients With High Risk Factors for Recurrence After Radical Surgery
In this study, 60 patients with HER2 overexpression UTUC with high-risk recurrence factors after radical surgery were proposed to be enrolled, and were assigned to Cohort I (receiving adjuvant therapy group) and Cohort II…
- Trial name
- NCT06210490
- Testing
- Disitamab Vedotin, Radiotherapy, Standard of Care
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking University First Hospital
Muscle Invasive Upper Tract Urothelial Carcinoma
Circulating and Urine Tumor DNA Dynamics Predict Minimal Residual Disease and Recurrence Risk in Locally Advanced Upper Tract Urothelial Carcinoma
In our study, the ultra-deep sequencing of circulating tumor DNA (ctDNA) and urine tumor DNA (utDNA) were performed to assess whether ctDNA and utDNA can be used as predictive biomarkers for the detection of minimal residual…
- Trial name
- NCT05595408
- Testing
- Adjuvant chemotherapy, adjuvant immunotherapy
- Where
- China
- Volunteers
- 84 people
- Sponsor
- RenJi Hospital
Upper Urinary Tract Urothelial Carcinoma, Kidney Preservation
Combination of DV and Tislelizumab for Renal Preservation in High-risk UTUC Patients
This is a prospective, open, multiple-center clinical study of renal preservation therapy in high-risk upper urinary tract urothelial carcinoma patients .
- Conditions
- Upper Urinary Tract Urothelial Carcinoma, Kidney Preservation, HER-2 ADC, PD-1antibody
- Trial name
- NCT05912816
- Testing
- RC48 Combined With Tislelizumab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- RenJi Hospital
Upper Tract Urothelial Carcinoma
Cisplatin-Based Chemotherapy Followed by Maintenance Avelumab in UTUC
A Prospective Phase II Study of Adjuvant Cisplatin-Based Chemotherapy followed by Maintenance Avelumab in Upper Tract Urothelial Carcinoma
- Trial name
- NCT07225374
- Testing
- Avelumab 10 mg/kg, Screening, Best Supportive Care (BSC)
- Where
- South Korea
- Volunteers
- 48 people
- Sponsor
- Samsung Medical Center
Upper Tract Urothelial Carcinoma
Ambulatory Flexible URS for UTUC Surveillance
This is a a prospective single-arm pilot study to investigate the safety and feasibility of flexible ureteroscopy under local anaesthesia.
- Trial name
- NCT06848868
- Testing
- Ambulatory flexible ureterorenoscopy
- Where
- 2 sites in Hong Kong
- Volunteers
- 10 people
- Sponsor
- Chinese University of Hong Kong
Upper Tract Urothelial Carcinoma, Neoadjuvant Therapy
Neoadjuvant Tislelizumab in Combination With Nab-Paclitaxel for UTUC
This study is designed as an open-label, single-arm, single center, phase II clinical trial, aiming to evaluate the efficacy of neoadjuvant Tislelizumab combined with Nab-Paclitaxel for patients with non-metastatic upper tract…
- Conditions
- Upper Tract Urothelial Carcinoma, Neoadjuvant Therapy, PD-1 Inhibitor, Nab-paclitaxel
- Trial name
- NCT07126119
- Testing
- Nab-Paclitaxel, Tislelizumab, Radical nephroureterectomy (RNU)
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Tianjin Medical University Second Hospital
Upper Tract Urothelial Carcinoma
Treatment of Tumors in the Urinary Collecting System of the Kidney or Ureter Using a Light Activated Drug (WST11)
The purpose of this study is to test the safety of a combination of the study drug called WST11 and PDT. Photodynamic therapy (PDT) is a type of ablation therapy (treatment which destroys tumor cells) which has been previously…
- Trial name
- NCT03617003
- Testing
- WST11 mediated vascular targeted phototherapy (VTP), Endoscopy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Upper Tract Urothelial Cancer
Single-Port RAS Using Da Vinci SP Surgical System for UTUC Patients
To evaluate patient-reported outcomes of radical nephroureterectomy using single-port robotic surgery
- Trial name
- NCT06987552
- Testing
- Da Vinci SP Surgical System
- Where
- Taiwan
- Volunteers
- 25 people
- Sponsor
- National Taiwan University Hospital
Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable, Upper Tract Urothelial Cancer
DDR Genes Alteration and Response to Platinum-based Chemotherapy in Advanced Urothelial Cancer.
This study aims to prospectively observe whether certain alterations in some genes related to the DNA repair mechanism are related to better response to platinum-based chemotherapy used to treat metastatic bladder or urothelial…
- Trial name
- SELECTIO-UC (NCT06820255)
- Testing
- Platinum + Gemcitabine, Avelumab first-line maintenance, NGS test for DDR alterations
- Where
- Italy
- Volunteers
- 135 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Upper Tract Urothelial Carcinoma
HEFTME System for Adjuvant Therapeutic Selection of Locally Advanced UTUC Postoperatively：A Perspective Cohort Study
This multicenter, real-world study introduces a novel Hematoxylin-eosin staining(H\&E)-based four tumor microenvironment (TME) system (HEFTME system) assisting in prognostic prediction and precise adjuvant treatment selection for…
- Trial name
- NCT06798246
- Testing
- Chemotherapy, Immunotherapy, ADC
- Volunteers
- 200 people
- Sponsor
- Peking University First Hospital
Carcinoma, Upper Tract Urothelial Carcinoma
A Study of RC48-ADC Combined with JS001 for Postoperative Adjuvant Treatment of Upper Tract Urothelial Carcinoma
This study will evaluate the efficacy and safety of intravenous RC48-ADC combined with JS001 in postoperative adjuvant therapy for HER2-positive upper tract urothelial carcinoma.
- Conditions
- Carcinoma, Upper Tract Urothelial Carcinoma, UTUC
- Trial name
- 1 (NCT05917158)
- Testing
- RC48-ADC and JS001
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Jinling Hospital, China
Renal Insufficiency, Upper Urinary Tract Urothelial Carcinoma
DV Combined With Toripalimab for Renal Preservation in Solitary Kidney or Renal Insufficiency or Bilateral Multiple UTUC
Approximately 20 participants will be enrolled in the study to evaluate the efficacy and safety of the combination of DV (DV, 2.0 mg/kg, intravenously administered every 2 weeks) and toripalimab (toripalimab, 3.0mg/kg…
- Conditions
- Renal Insufficiency, Upper Urinary Tract Urothelial Carcinoma, Solitary Kidney
- Trial name
- NCT06354231
- Testing
- DV, Toripalimab, Laser surgery
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Fudan University